カレントテラピー　36-9　サンプル page 10/28

このページは カレントテラピー　36-9　サンプル の電子ブックに掲載されている10ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　36-9　サンプル

Current Therapy 2018 Vol.36 No.9 13分子標的薬剤とコンパニオン診断薬，バイオマーカー845癌」の効能効果でダコミチニブの日本国内における製造販売承認申請が2018年5月に行われている．参考文献1）Lynch TJ, Bell DW, Sordella R, et al：Activating mutationsin the epidermal growth factor receptor underlying responsivenessof non-small-cell lung cancer to gefitinib. N Engl JMed 350：2129-2139, 20042）Paez JG, Janne PA, Lee JC, et al：EGFR mutations in lungcancer：correlation with clinical response to gefitinib therapy.Science 304：1497-1500, 20043）Pao W, Miller V, Zakowski M, et al：EGF receptor genemutations are common in lung cancers from“ never smokers”and are associated with sensitivity of tumors to gefitinib anderlotinib. Proc Natl Acad Sci U S A 101：13306-13311, 20044）Dearden S, Stevens J, Wu YL, et al：Mutation incidence andcoincidence in non small-cell lung cancer：meta-analyses byethnicity and histology（mutMap）. Ann Oncol 24：2371-2376, 20135）日本肺癌学会バイオマーカー委員会：肺癌患者におけるEGFR遺伝子変異検査の手引き 第3.05版．2016（https://www.haigan.gr.jp/uploads/files/photos/1329.pdf）（2018年7月閲覧）6）Cadranel J：Osimertinib in first-line treatment-is a comparisonnot proof ? Ann Transl Med 6：57, 20187）Girard N：Optimizing outcomes in EGFR mutation-positiveNSCLC：which tyrosine kinase inhibitor and when? FutureOncol 14：1117-1132, 20188）Yang JC, Wu YL, Schuler M, et al：Afatinib versus cisplatinbasedchemotherapy for EGFR mutation-positive lung adenocarcinoma（LUX-Lung 3 and LUX-Lung 6）：analysis ofoverall survival data from two randomised, phase 3 trials.Lancet Oncol 16：141-151, 20159）Urata Y, Katakami N, Morita S, et al：Randomized Phase ⅢStudy Comparing Gefitinib With Erlotinib in Patients WithPreviously Treated Advanced Lung Adenocarcinoma：WJOG 5108L. J Clin Oncol 34：3248-3257, 201610）Park K, Tan EH, O’Byrne K, et al：Afatinib versus gefitinibas first-line treatment of patients with EGFR mutation-positivenon-small-cell lung cancer（LUX-Lung 7）：a phase 2B,open-label, randomised controlled trial. Lancet Oncol 17：577-589, 201611）Wu YL, Cheng Y, Zhou X, et al：Dacomitinib versus gefitinibas first-line treatment for patients with EGFR-mutationpositivenon-small-cell lung cancer（ARCHER 1050）：a randomised,open-label, phase 3 trial. Lancet Oncol 18：1454-1466, 201712）Liang W, Wu X, Fang W, et al：Network meta-analysis oferlotinib, gefitinib, afatinib and icotinib in patients withadvanced non-small-cell lung cancer harboring EGFR mutations.PLoS One 9：e85245, 201413）Yu HA, Arcila ME, Rekhtman N, et al：Analysis of tumorspecimens at the time of acquired resistance to EGFR-TKItherapy in 155 patients with EGFR -mutant lung cancers.Clin Cancer Res 19：2240-2247, 201314）Sequist LV, Waltman BA, Dias-Santagata D, et al：Genotypicand histological evolution of lung cancers acquiring resistanceto EGFR inhibitors. Sci Transl Med 3：75ra26, 201115）Mok TS, Wu YL, Ahn MJ, et al；AURA3 Investigators：Osimertinib or Platinum-Pemetrexed in EGFR T790M-PositiveLung Cancer. N Engl J Med 376：629-640, 201716）Soria JC, Ohe Y, Vansteenkiste J, et al：Osimertinib inUntreated EGFR-Mutated Advanced Non-Small-Cell LungCancer. N Engl J Med 378：113-125, 201817）Yu HA, Tian SK, Drilon AE, et al：Acquired Resistance ofEGFR -Mutant Lung Cancer to a T790M -Specific EGFRInhibitor：Emergence of a Third Mutation（C797S）in theEGFR Tyrosine Kinase Domain. JAMA Oncol 1：982-984,201518）Santarpia M, Liguori A, Karachaliou N, et al：Osimertinib inthe treatment of non-small-cell lung cancer：design, developmentand place in therapy. Lung Cancer（Auckl）8：109-125, 201719）Wu JY, Yu CJ, Chang YC, et al：Effectiveness of tyrosinekinase inhibitors on "uncommon" epidermal growth factorreceptor mutations of unknown clinical significance in nonsmallcell lung cancer. Clin Cancer Res 17：3812-3821, 201120）Yang JC, Sequist LV, Geater SL, et al：Clinical activity ofafatinib in patients with advanced non-small-cell lung cancerharbouring uncommon EGFR mutations：a combinedpost-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUXLung6. Lancet Oncol 16：830-838, 201521）Paz-Ares L, et al：Afatinib（A）vs Gefitinib（G）in patients（PTS）with EGFR mutation -positive（EGFRm+）non -small -cell lung cancer（NSCLC）：ovevall survival（OS）data from the phase Ⅱb trial LUX-Lung 7（LL7）. Abstract# LBA43 presented at the European Society for MedicalOncology（ESMO）2016 congress in Copenhagen, Denmark,7-11 October※ 紙面の都合上一部レビューを文献として引用している．オリジナル論文はレビュー文献から各自参照されたい．